Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalbavancin vs SOC in Osteomyelitis
NCT03091439Phase 2Terminated
- Sponsor
- Allergan
- Start
- May 2017
- Primary completion
- Aug 2017
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in osteomyelitis (OM) comparing Dalbavancin with Standard of Care (2 arms). Primary endpoint: Number of Participants With Clinical Response at Day 42 in the Clinically Evaluable (CE) Population. Started May 2017; status: terminated.
02
Drugs
dalbavancin
03
Conditions
osteomyelitis (OM)
Beyond the preview
Go deeper on NCT03091439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03091439.